

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

11 Jul 2026

### Evaluation of efficacy of topiramate alone and topiramate with omega-3 fatty acid in prophylaxis of headaches in 5-15 year old children with migraine

#### Protocol summary

##### Study aim

Topiramate and topiramate with omega-3 in pediatric migraine

##### Design

A randomized parallel group clinical trial

##### Settings and conduct

This study will be done to answer this question that whether or not topiramate with omega-3 capsule is more efficient than topiramate alone in reduction of monthly frequency, severity, and disability score of headaches of without vitamin D3 deficiency migraineur children. In a clinical trial, sixty 5-15 year old children with migraine headache, who would be referred to pediatric neurology clinic of Shahid Sadoughi University of Medical Sciences, Yazd, Iran and prophylactic therapy would be indicated in them, will be distributed randomly into two groups. In group I, 2 mg/kg/day of topiramate and in group II, 2mg/kg/day of topiramate and one capsule of omega-3 daily will be given. The drugs will be continued for two months and the children will be followed up monthly for two consecutive months. Primary outcomes include monthly frequency, severity, duration and disability score of migraine headache that will be compared before and after two months of treatment. Severity of headache will be assessed by asking each child to grade majority of headache pain on 10-point scale as no pain = scale of 0 and the most severe pain = 10. Headaches disability will be assessed by Pediatric Migraine Disability Assessment score questionnaire. Secondary outcome include more than 50 % of reduction in monthly headache frequency and clinical side effects. The trial uses computer generated equal simple randomization by random numbers

##### Participants/Inclusion and exclusion criteria

5-15 year old children with migraine

##### Intervention groups

In group.I topiramate 2mg/kg/day , group.II topiramate

2mg/kg/day and omega-3 daily

##### Main outcome variables

Monthly frequency of headache

#### General information

##### Reason for update

##### Acronym

-

##### IRCT registration information

IRCT registration number: **IRCT20091027002639N23**

Registration date: **2020-03-31, 1399/01/12**

Registration timing: **registered\_while\_recruiting**

Last update: **2020-03-31, 1399/01/12**

Update count: **0**

##### Registration date

2020-03-31, 1399/01/12

##### Registrant information

###### Name

Razieh Fallah

###### Name of organization / entity

Shahid Sadoughi University of Medical Sciences, Yazd, Iran

###### Country

Iran (Islamic Republic of)

###### Phone

+98 35 3822 4000

###### Email address

fallah@ssu.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2019-03-07, 1397/12/16

##### Expected recruitment end date

2020-04-19, 1399/01/31

**Actual recruitment start date**

empty

**Actual recruitment end date**

empty

**Trial completion date**

empty

**Scientific title**

Evaluation of efficacy of topiramate alone and topiramate with omega-3 fatty acid in prophylaxis of headaches in 5-15 year old children with migraine

**Public title**

Efficacy of topiramate and topiramate with omega-3 fatty acid in prophylaxis of children migraine headaches

**Purpose**

Prevention

**Inclusion/Exclusion criteria**

**Inclusion criteria:**

children aged 5-15 years old having migraine headache based on International Headache Society Criteria having one or more headache attack per week having moderate or severe headache disability have not received omega-3 combinations within the past two months did not use any migraine preventive therapy

**Exclusion criteria:**

secondary headaches such as epilepsy or other neurologic disorders allergy to topiramate or omega-3 discontinuation of drugs usage for more than one week irregular drugs usage

**Age**

From **5 years** old to **15 years** old

**Gender**

Both

**Phase**

2-3

**Groups that have been masked**

*No information*

**Sample size**

Target sample size: **60**

**Randomization (investigator's opinion)**

Randomized

**Randomization description**

Participants are randomly assigned following simple randomization procedures (computerized random numbers) to 1 of 2 treatment groups and allocation ratio was 1:1 for the two groups.

**Blinding (investigator's opinion)**

Not blinded

**Blinding description**

**Placebo**

Not used

**Assignment**

Parallel

**Other design features**

**Secondary Ids**

empty

## Ethics committees

1

**Ethics committee**

**Name of ethics committee**

of Shahid Sadoughi University of Medical Sciences, Yazd, Iran

**Street address**

Central building of university, Bahonar square

**City**

Yazd

**Province**

Yazd

**Postal code**

8915836846

**Approval date**

2019-03-06, 1397/12/15

**Ethics committee reference number**

IR.SSU.MEDICINE.REC.1398.027

## Health conditions studied

1

**Description of health condition studied**

migraine headache

**ICD-10 code**

G43

**ICD-10 code description**

Migraine

## Primary outcomes

1

**Description**

Monthly frequency of headache

**Timepoint**

Before and two months after treatment

**Method of measurement**

Asking from patient

2

**Description**

Severity of headache

**Timepoint**

Before and two months after treatment

**Method of measurement**

Asking from patient

3

**Description**

Duration of headache

**Timepoint**

Before and two months after treatment

**Method of measurement**

Asking from patient

## 4

### Description

Pediatric Migraine Disability score

### Timepoint

Before and two months after treatment

### Method of measurement

Questionnaire

## Secondary outcomes

### 1

#### Description

Clinical side effects

#### Timepoint

Before and two months after treatment

#### Method of measurement

Clinical exam and asking from patients

## Intervention groups

### 1

#### Description

Control group: Tablet of 25 and 50 mg of topiramate of Daroupakhsh Co, Iran in dosage of 2 mg/kg/day single dose for two months

#### Category

Treatment - Drugs

### 2

#### Description

Intervention group: One daily capsule of omega-3 from 21st Century Co, USA and and tablet of 25 and 50 mg of topiramate of Daroupakhsh Co, Iran in dosage of 2 mg/kg/day single dose for two months

#### Category

Treatment - Drugs

## Recruitment centers

### 1

#### Recruitment center

##### Name of recruitment center

Pediatric Neurology Clinic of Shahid Sadoughi University of Medical Sciences, Yazd, Iran

##### Full name of responsible person

Dr. Raziieh Fallah

##### Street address

Shahid Sadoughi Hospital, Ebnsina Blvd, Shahid Ghandi Blvd

##### City

Yazd

##### Province

Yazd

##### Postal code

8915887857

##### Phone

+98 35 3822 4000

#### Fax

+98 35 3822 4100

#### Email

FALLAH@yahoo.com

## Sponsors / Funding sources

### 1

#### Sponsor

##### Name of organization / entity

Yazd University of Medical Sciences

##### Full name of responsible person

Dr.Masoud Mirzaei

##### Street address

Central building of university, Bahonar Square

##### City

Yazd

##### Province

Yazd

##### Postal code

8915887857

##### Phone

+98 35 3724 0171

##### Email

mmirzaei@ssu.ac.ir

#### Grant name

#### Grant code / Reference number

#### Is the source of funding the same sponsor organization/entity?

Yes

#### Title of funding source

Yazd University of Medical Sciences

#### Proportion provided by this source

100

#### Public or private sector

Public

#### Domestic or foreign origin

Domestic

#### Category of foreign source of funding

empty

#### Country of origin

#### Type of organization providing the funding

Academic

## Person responsible for general inquiries

#### Contact

##### Name of organization / entity

Yazd University of Medical Sciences

##### Full name of responsible person

Dr.Raziieh Fallah

##### Position

Professor, Pediatric Neurologist

##### Latest degree

Subspecialist

##### Other areas of specialty/work

Neurology

##### Street address

بلوار شهید قندی - بلوار ابن سینا - بیمارستان شهید صدوقی

##### City

Yazd

**Province**

Yazd

**Postal code**

8915887857

**Phone**

+93 53 822 4000

**Fax**

+98 35 3822 4100

**Email**

FALLAH@ssu.ac.ir

**Person responsible for scientific inquiries****Contact****Name of organization / entity**

Yazd University of Medical Sciences

**Full name of responsible person**

Dr.Razieh Fallah

**Position**

Professor, Pediatric Neurologist

**Latest degree**

Subspecialist

**Other areas of specialty/work**

Neurology

**Street address**

Shahid Sadoughi Hospital, Ebnsina Blvd, Shahid Ghandi Blvd

**City**

Yazd

**Province**

Yazd

**Postal code**

8915887857

**Phone**

+98 35 3822 4000

**Fax**

+98 35 3822 4100

**Email**

dr.raziehfallah@yahoo.com

**Person responsible for updating data****Contact****Name of organization / entity**

Yazd University of Medical Sciences

**Full name of responsible person**

Dr.Razieh Fallah

**Position**

Pediatric Neurologist, Professor

**Latest degree**

Subspecialist

**Other areas of specialty/work**

Neurology

**Street address**

Shahid Sadoughi Hospital, Ebnsina Blvd, Shahid Ghandi Blvd

**City**

Yazd

**Province**

Yazd

**Postal code**

8915898857

**Phone**

+98 35 3822 4000

**Fax**

+98 35 3822 4100

**Email**

dr.raziehfallah@yahoo.com

**Sharing plan****Deidentified Individual Participant Data Set (IPD)**

Undecided - It is not yet known if there will be a plan to make this available

**Study Protocol**

No - There is not a plan to make this available

**Statistical Analysis Plan**

No - There is not a plan to make this available

**Informed Consent Form**

No - There is not a plan to make this available

**Clinical Study Report**

No - There is not a plan to make this available

**Analytic Code**

No - There is not a plan to make this available

**Data Dictionary**

No - There is not a plan to make this available